Literature DB >> 21191494

Guidelines for the management of castrate-resistant prostate cancer.

Fred Saad1, Sebastien J Hotte.   

Abstract

Entities:  

Year:  2010        PMID： 21191494      PMCID： PMC2997826          DOI： 10.5489/cuaj.10167

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  29 in total

1.  Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

Authors:  I F Tannock; D Osoba; M R Stockler; D S Ernst; A J Neville; M J Moore; G R Armitage; J J Wilson; P M Venner; C M Coppin; K C Murphy
Journal:  J Clin Oncol       Date:  1996-06       Impact factor: 44.544

2.  Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study.

Authors:  Jean-Christophe Eymard; Stéphane Oudard; Gwenaelle Gravis; Jean-Marc Ferrero; Christine Theodore; Florence Joly; Frank Priou; Ivan Krakowski; Alain Zannetti; Laurence Thill; Philippe Beuzeboc
Journal:  BJU Int       Date:  2010-03-09       Impact factor: 5.588

3.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

Authors:  Daniel P Petrylak; Catherine M Tangen; Maha H A Hussain; Primo N Lara; Jeffrey A Jones; Mary Ellen Taplin; Patrick A Burch; Donna Berry; Carol Moinpour; Manish Kohli; Mitchell C Benson; Eric J Small; Derek Raghavan; E David Crawford
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

4.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

5.  Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.

Authors:  Fred Saad; Donald M Gleason; Robin Murray; Simon Tchekmedyian; Peter Venner; Louis Lacombe; Joseph L Chin; Jeferson J Vinholes; J Allen Goas; Ming Zheng
Journal:  J Natl Cancer Inst       Date:  2004-06-02       Impact factor: 13.506

6.  Denosumab in men receiving androgen-deprivation therapy for prostate cancer.

Authors:  Matthew R Smith; Blair Egerdie; Narciso Hernández Toriz; Robert Feldman; Teuvo L J Tammela; Fred Saad; Jiri Heracek; Maciej Szwedowski; Chunlei Ke; Amy Kupic; Benjamin Z Leder; Carsten Goessl
Journal:  N Engl J Med       Date:  2009-08-11       Impact factor: 91.245

7.  Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).

Authors:  Eric J Small; Susan Halabi; Nancy A Dawson; Walter M Stadler; Brian I Rini; Joel Picus; Preston Gable; Frank M Torti; Ellen Kaplan; Nicholas J Vogelzang
Journal:  J Clin Oncol       Date:  2004-03-15       Impact factor: 44.544

8.  Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma.

Authors:  J A Storlie; J C Buckner; G A Wiseman; P A Burch; L C Hartmann; R L Richardson
Journal:  Cancer       Date:  1995-07-01       Impact factor: 6.860

Review 9.  Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.

Authors:  Terrence H Diamond; Celestia S Higano; Matthew R Smith; Theresa A Guise; Frederick R Singer
Journal:  Cancer       Date:  2004-03-01       Impact factor: 6.860

10.  Radiotherapy fractionation for the palliation of uncomplicated painful bone metastases - an evidence-based practice guideline.

Authors:  Jackson Sai-Yiu Wu; Rebecca K S Wong; Nancy S Lloyd; Mary Johnston; Andrea Bezjak; Timothy Whelan
Journal:  BMC Cancer       Date:  2004-10-04       Impact factor: 4.430
View more
  45 in total

Review 1.  Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies.

Authors:  Cameron M Armstrong; Allen C Gao
Journal:  Am J Clin Exp Urol       Date:  2015-08-08

2.  Bioinformatics analyses of publicly available NEPCa datasets.

Authors:  Siyuan Cheng; Xiuping Yu
Journal:  Am J Clin Exp Urol       Date:  2019-10-15

Review 3.  Intravenous therapies for castration-resistant prostate cancer: toxicities and adverse events.

Authors:  Eric A Singer; Ramaprasad Srinivasan
Journal:  Urol Oncol       Date:  2011-10-19       Impact factor: 3.498

4.  Metastatic castration-resistant prostate cancer: The emerging continuum of care.

Authors:  Fred Saad
Journal:  Can Urol Assoc J       Date:  2013 Jan-Feb       Impact factor: 1.862

5.  Circulating tumor cell-based or tissue biopsy-based AR-V7 detection: which provides the greatest clinical utility?

Authors:  Arpit Rao; Emmanuel S Antonarakis
Journal:  Ann Transl Med       Date:  2019-12

Review 6.  Radium-223 dichloride: a review of its use in patients with castration-resistant prostate cancer with symptomatic bone metastases.

Authors:  Matt Shirley; Paul L McCormack
Journal:  Drugs       Date:  2014-04       Impact factor: 9.546

7.  MicroRNA-181a promotes docetaxel resistance in prostate cancer cells.

Authors:  Cameron M Armstrong; Chengfei Liu; Wei Lou; Alan P Lombard; Christopher P Evans; Allen C Gao
Journal:  Prostate       Date:  2017-06       Impact factor: 4.104

8.  Real-World Corticosteroid Utilization Patterns in Patients with Metastatic Castration-Resistant Prostate Cancer in 2 Large US Administrative Claims Databases.

Authors:  Marie-Hélène Lafeuille; Jonathan Gravel; Amanda Grittner; Patrick Lefebvre; Lorie Ellis; R Scott McKenzie
Journal:  Am Health Drug Benefits       Date:  2013-07

9.  Management of skeletal-related events in patients with advanced prostate cancer and bone metastases: Incorporating new agents into clinical practice.

Authors:  Alan So; Joseph Chin; Neil Fleshner; Fred Saad
Journal:  Can Urol Assoc J       Date:  2012-12       Impact factor: 1.862

10.  XGEVA(®) (denosumab).

Authors: 
Journal:  Can Urol Assoc J       Date:  2015 May-Jun       Impact factor: 1.862
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.